Related Experiment Videos
Therapeutic potential of Ampligen
1Department of Neoplastic Diseases, Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
American Family Physician
|October 1, 1987
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.
Annals of internal medicine·2001
Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?
American journal of clinical oncology·2001
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2000
Nausea and Vomiting During Pregnancy.
American family physician·2026
Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.
American family physician·2026
Type 2 Diabetes: Outpatient Insulin Management.
American family physician·2026
Recurrent UTI in Women: Diagnosis and Management.
American family physician·2026
Gambling Disorder: Diagnosis and Treatment.
American family physician·2026
Pacemaker Therapy: Indications and Recommendations.
American family physician·2026
Development of a Novel, Eco-Friendly Mechanical Cell Lysis Process Using Hollow Fiber Filter for AAV Manufacturing.
Biotechnology and bioengineering·2026
Programmed repair of disease-causing UGA premature termination codons in mammalian brain.
Nucleic acids research·2026
Molecular profiling and functional analyses of umbilical cord mesenchymal stem cell-derived extracellular vesicles for dry eye diseases.
Extracellular vesicles and circulating nucleic acids·2026
Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.
Frontiers in immunology·2026
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
The Journal of clinical and aesthetic dermatology·2026